Bromocriptine – unique formulation of a dopamine agonist for the treatment of type 2 diabetes

Bibliography

• Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-94
   PubMed Web of Science ®Google Scholar
• Bonora E, Kiechl S, Willeit J, Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes 2004;53:1782-9
   PubMed Web of Science ®Google Scholar
• Sahay BK, Sahay RK. Hypertension in diabetes. J Indian Med Assoc 2003;101:12,14-15
   Google Scholar
• Haffner SM. Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. Am J Cardiol 2002;90:55i-61i
   PubMed Web of Science ®Google Scholar
• Sam S, Haffner S, Davidson MH, Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes. Diabetes 2008;57:2022-7
   PubMedGoogle Scholar
• Kelley DE, McKolanis TM, Hegazi RA, Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003;285:E906-16
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rifai N, C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34
   PubMed Web of Science ®Google Scholar
• Haffner SM, Stern MP, Hazuda HP, Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-8
   PubMed Web of Science ®Google Scholar
• D'Agostino RB Jr, Hamman RF, Karter AJ, Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care 2004;27:2234-40
   PubMed Web of Science ®Google Scholar
• Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002;51:1131-7
   PubMed Web of Science ®Google Scholar
• Toutouzas K, Markou V, Drakopoulou M, Patients with type two diabetes mellitus: increased local inflammatory activation in culprit atheromatous plaques. Hellenic J Cardiol 2005;46:283-8
   PubMedGoogle Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115-26
   PubMed Web of Science ®Google Scholar
• Hwang JS, Wu TL, Chou SC, Development of multiple complications in type 2 diabetes is associated with the increase of multiple markers of chronic inflammation. J Clin Lab Anal 2008;22:6-13
   PubMedGoogle Scholar
• Ceriello A, Colagiuri S. International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabet Med 2008;25:1151-6
   PubMed Web of Science ®Google Scholar
• Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is … or is it? Lancet 1997;350(Suppl 1):SI4-9
   PubMedGoogle Scholar
• Komoroski B, Vachharajani N, Feng Y, Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85:513-19
   PubMed Web of Science ®Google Scholar
• Nakade Y, Tsukamoto K, Pappas TN, Takahashi T. Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats. Brain Res 2006;1111:117-21
   PubMedGoogle Scholar
• Cabou C, Campistron G, Marsollier N, Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 2008;57:2577-87
   PubMed Web of Science ®Google Scholar
• Kim D, MacConell L, Zhuang D, Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93
   PubMed Web of Science ®Google Scholar
• Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009;11(Suppl 3):26-34
   PubMedGoogle Scholar
• Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 2007;11:113-33
   PubMed Web of Science ®Google Scholar
• Cincotta A. Hypothalamic role in the insulin resistance syndrome. In: Hansen B, Shaffrir E, editors, Reistance and insulin resistance syndrome. Taylor & Francis: London; 2002. p. 271-312
   Google Scholar
• Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996;19:667-70
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Meier AH, Cincotta M Jr. Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999;8:1683-707
   PubMedGoogle Scholar
• Meier A, Cincotta A. Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Rev 1996;4:464-87
   Google Scholar
• Luo S, Ezrokhi M, Trubitsyna Y, Cincotta AH. Intrahypothalamic circuitry regulating hypothalamic fuel sensing to induce insulin sensitivity or insulin resistance [abstract]. Diabetologia 2008;51(Suppl 1):S59
   Google Scholar
• Ezrokhi M, Luo S, Cincotta J, Cincotta AH. Timed dopmaine agonist therapy induces a postprandial-selective insulin sensitivity. Diabetologia 2008;51(Suppl 1):S276
   PubMedGoogle Scholar
• Luo S, Liang Y, Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology 1999;69:160-6
   PubMed Web of Science ®Google Scholar
• Luo S, Luo J, Meier AH, Cincotta AH. Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance. Neuroreport 1997;8:3495-9
   PubMed Web of Science ®Google Scholar
• Luo S, Luo J, Cincotta AH. Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters. Neuroreport 1999;10:2073-7
   PubMed Web of Science ®Google Scholar
• Luo S, Meier AH, Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology 1998;68:1-10
   PubMed Web of Science ®Google Scholar
• Maurer G, Schreier E, Delaborde S, Fate and disposition of bromocriptine in animals and man. I: structure elucidation of the metabolites. Eur J Drug Metab Pharmacokinet 1982;7:281-92
   PubMed Web of Science ®Google Scholar
• Luo S, Luo J, Cincotta AH. Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology 1999;70:460-5
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Luo S, Zhang Y, Chronic infusion of norepinephrine into the VMH of normal rats induces the obese glucose-intolerant state. Am J Physiol Regul Integr Comp Physiol 2000;278:R435-44
   PubMed Web of Science ®Google Scholar
• Norvartis. Parlodel Package Insert, 2005. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/017962s063,064lbl.pdf [Last accessed 28 September 2009]
   Google Scholar
• Loew DM. Effects on the central nervous system. In: Berde H, Schild H, editors, Ergot alkaloids and related compounds. Springer-Verlag: New York; 1978. p. 421-532
   Google Scholar
• Pijl H, Ohashi S, Matsuda M, Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000;23:1154-61
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Schiller BC, Meier AH. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Metabolism 1991;40:639-44
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Schiller BC, Landry RJ, Circadian neuroendocrine role in age-related changes in body fat stores and insulin sensitivity of the male Sprague-Dawley rat. Chronobiol Int 1993;10:244-58
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Meier AH. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metabolism 1995;44:1349-55
   PubMed Web of Science ®Google Scholar
• Cincotta AH, MacEachern TA, Meier AH. Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol 1993;264:E285-93
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Meier AH. Prolactin permits the expression of a circadian variation in lipogenic responsiveness to insulin in hepatocytes of the golden hamster (Mesocricetus auratus). J Endocrinol 1985;106:173-6
   PubMed Web of Science ®Google Scholar
• Scranton RE, Gaziano JM, Rutty D. A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo. BMC Endocr Disord 2007;7:3
   PubMedGoogle Scholar
• VeroScience. Cycloset Package Insert, 2009. FDA approved label. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020866lbl.pdf [Last accessed 23 September 2009]
   Google Scholar
• Parks M. Cycloset FDA Approval Letter, 2009. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/020866s000ltr.pdf [Last accessed 23 September 2009]
   Google Scholar